WallStreetZenWallStreetZen

NYSE: DVA
DAVITA INC Stock Forecast, Predictions & Price Target

Analyst price target for DVA

Based on 5 analysts offering 12 month price targets for DAVITA INC.
Min Forecast
$111.00+18.83%
Avg Forecast
$146.80+57.16%
Max Forecast
$207.00+121.6%

Should I buy or sell DVA stock?

Based on 5 analysts offering ratings for DAVITA INC.
Hold
Strong Buy
1 analysts 20%
Buy
0 analysts 0%
Hold
4 analysts 80%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

DVA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Truist Securities
Top 6%
95
HoldMaintains$125.00+33.82%2022-01-05
RBC Capital
Bottom 4%
4
HoldMaintains$111.00+18.83%2021-10-29
Cowen & Co.
Bottom 6%
6
HoldInitiates Coverage On$145.00+55.23%2021-09-10
Barclays
Bottom 9%
9
HoldDowngrades$146.00+56.30%2021-08-12
Deutsche Bank
Bottom 20%
20
Strong BuyMaintains$207.00+121.60%2021-07-19

1 of 1

Forecast return on equity

Is DVA forecast to generate an efficient return?
Company
116.38%
Industry
-72.12%
Market
34.95%
DVA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is DVA forecast to generate an efficient return on assets?
Company
5.75%
Industry
7%
DVA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

DVA earnings per share forecast

What is DVA's earnings per share in the next 2 years based on estimates from 3 analysts?
Avg 1 year Forecast
$7.79-11.58%
Avg 2 year Forecast
$10.38+17.82%
DVA's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

DVA revenue forecast

What is DVA's revenue in the next 2 years based on estimates from 3 analysts?
Avg 1 year Forecast
$11.8B+1.78%
Avg 2 year Forecast
$12.2B+5.03%
DVA's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

DVA earnings growth forecast

How is DVA forecast to perform vs Medical Care Facilities companies and vs the US market?
Company
-11.58%
Industry
-2.46%
Market
37.65%
DVA's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
DVA's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
DVA's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

DVA revenue growth forecast

How is DVA forecast to perform vs Medical Care Facilities companies and vs the US market?
Company
1.78%
Industry
6.31%
Market
12.79%
DVA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
DVA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

DVA vs Medical Care Facility Stocks

TickerPricePrice TargetUp/downsideConsensus
DVA$93.41$146.80+57.16%Hold
UHS$121.41$146.42+20.60%Hold
AGL$18.80$36.33+93.26%Strong Buy
CHE$494.59$585.50+18.38%Buy
THC$62.22$100.88+62.14%Strong Buy

DAVITA Stock Forecast FAQ

Is DAVITA Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NYSE: DVA) stock is to Hold DVA stock.

Out of 5 analysts, 1 (20%) are recommending DVA as a Strong Buy, 0 (0%) are recommending DVA as a Buy, 4 (80%) are recommending DVA as a Hold, 0 (0%) are recommending DVA as a Sell, and 0 (0%) are recommending DVA as a Strong Sell.

What is DVA's earnings growth forecast for 2022-2023?

(NYSE: DVA) DAVITA's forecast annual earnings growth rate of -11.58% is not forecast to beat the US Medical Care Facilities industry's average forecast earnings growth rate of -2.46%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 37.65%.

DAVITA's earnings in 2022 is $903,169,000.On average, 3 Wall Street analysts forecast DVA's earnings for 2022 to be $736,934,000, with the lowest DVA earnings forecast at $733,150,000, and the highest DVA earnings forecast at $739,772,000.

In 2023, DVA is forecast to generate $981,948,000 in earnings, with the lowest earnings forecast at $963,028,000 and the highest earnings forecast at $993,300,000.

What is DVA's revenue growth forecast for 2022-2023?

(NYSE: DVA) DAVITA's forecast annual revenue growth rate of 1.78% is not forecast to beat the US Medical Care Facilities industry's average forecast revenue growth rate of 6.31%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.79%.

DAVITA's revenue in 2022 is $11,616,351,000.On average, 3 Wall Street analysts forecast DVA's revenue for 2022 to be $1,118,501,775,600, with the lowest DVA revenue forecast at $1,114,577,200,000, and the highest DVA revenue forecast at $1,126,210,162,000.

In 2023, DVA is forecast to generate $1,154,219,330,000 in revenue, with the lowest revenue forecast at $1,145,795,200,000 and the highest revenue forecast at $1,164,946,970,000.

What is DVA's forecast return on assets (ROA) for 2022-2023?

(NYSE: DVA) forecast ROA is 5.75%, which is lower than the forecast US Medical Care Facilities industry average of 7%.

What is DVA's Price Target?

According to 5 Wall Street analysts that have issued a 1 year DVA price target, the average DVA price target is $146.80, with the highest DVA stock price forecast at $207.00 and the lowest DVA stock price forecast at $111.00.

On average, Wall Street analysts predict that DAVITA's share price could reach $146.80 by Jan 5, 2023. The average DAVITA stock price prediction forecasts a potential upside of 57.16% from the current DVA share price of $93.41.

What is DVA's Earnings Per Share (EPS) forecast for 2022-2023?

(NYSE: DVA) DAVITA's current Earnings Per Share (EPS) is $8.81. On average, analysts forecast that DVA's EPS will be $7.79 for 2022, with the lowest EPS forecast at $7.75, and the highest EPS forecast at $7.82. In 2023, DVA's EPS is forecast to hit $10.38 (min: $10.18, max: $10.50).

What is DVA's forecast return on equity (ROE) for 2022-2023?

(NYSE: DVA) forecast ROE is 116.38%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.